Liposome: A Novel Carrier for Targeting Drug Delivery System
DOI:
https://doi.org/10.22270/ajprd.v8i4.802Keywords:
Targeted drug delivery system, Encapsulation, Vesicular system, MacrophagesAbstract
Targeted drug delivery, sometimes called Smart drug delivery is a method of delivering active molecules to the target site by increasing the concentration of active molecules and produces the desired effects without disturbing the bio-environment. This system is based on a technique that delivers precise amount of an active ingredient for a prolonged period of time to a targeted diseased area inside the body. This helps to maintain the specified plasma and tissue drug levels within the body, thereby preventing any harm to the healthy tissue via the drug. It is advantageous in terms of reduction in the frequency of administration, having a more uniform effect of the drug, reduction of side-effects and reduced fluctuation in circulating drug levels. Among several vesicular drug delivery systems, Liposome have attracted a lot of attention than alternative systems because of several meritable features like excellent chemical and biological stability, good solubilization power, promote intracellular delivery of bio-active molecules, reduce the uptake of macrophages and encapsulate each hydrophilic in addition as lipophilic drug molecules. The focus of this review is to discuss liposome with special emphasis on targeting of drugs.
Downloads
References
2. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitroefficacy on ovarian cancer cells. Cancer Research. 2016; 76(14):2065.
3. Scott R, Crabbe D, Krynska B, Ansari R, Kiani M. Aiming for the heart: Targeted delivery of drugs to diseased cardiac tissue. Expert opinion on drug delivery. 2008; 5:459-70.
4. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports : PR. 2012; 64(5):1020-37.
5. Swaminathan J, Ehrhardt C. Liposomal delivery of proteins and peptides. Expert Opin Drug Deliv. 2012;9(12):1489-503.
6. Hemal Tandel PB, Keerti Jain, Aliasgar Shahiwala, Ambikanandan Misra. In-Vitro and In-Vivo Tools in Emerging Drug Delivery Scenario: Challenges and Updates. In: Misra ASaA, editor. In-Vitro and In-Vivo Tools in Drug Delivery Research for Optimum Clinical Outcomes: CRC Press; 2018.
7. Manish G, Vimukta S, editors. Targeted drug delivery system: A Review2011.
8. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018; 536(1):95-107.
9. Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. Journal of drug targeting. 2012; 20(10):813-30.
10. Bangham AD. A correlation between surface charge and coagulant action of phospholipids. Nature. 1961; 192:1197-8.
11. Johnston MJ, Semple SC, Klimuk SK, Ansell S, Maurer N, Cullis PR. Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin. Biochimica et biophysica acta. 2007; 1768(5):1121-7.
12. Huwyler J, Drewe J, Krähenbuhl S. Tumor targeting using liposomal antineoplastic drugs. International journal of nanomedicine. 2008; 3(1):21-9.
13. Patel P, Hanini A, Shah A, Patel D, Patel S, Bhatt P, et al. Surface Modification of Nanoparticles for Targeted Drug Delivery. In: Pathak YV, editor. Surface Modification of Nanoparticles for Targeted Drug Delivery. Cham: Springer International Publishing; 2019. p. 19-31.
14. Chow TH, Lin YY, Hwang JJ, Wang HE, Tseng YL, Wang SJ, et al. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model. Anticancer research. 2009; 29(6):2111-20.
15. Torchilin VP. Multifunctional nanocarriers. Advanced drug delivery reviews. 2006;58(14):1532-55.
16. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert opinion on biological therapy. 2001; 1(6):923-47.
17. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013; 8(1):102-.
18. Moghimipour E, Handali S. Liposomes as Drug Delivery Systems: Properties and Applications. Research Journal of Pharmaceutical, Biological and Chemical. 2013; 4(1):169-85.
19. Lim SB, Banerjee A, Önyüksel H. Improvement of drug safety by the use of lipid-based nanocarriers. Journal of controlled release : official journal of the Controlled Release Society. 2012; 163(1):34-45.
20. Kumar S, Sharma P, Bansal M, Malviya R. LIPOSOME – A NOVEL COLLOIDAL DRUG DELIVERY SYSTEM. Journal of Chronotherapy and Drug Delivery. 2011; 2:7-13.
21. Garg T, Singh O, Arora S, Murthy R. Scaffold: a novel carrier for cell and drug delivery. Critical reviews in therapeutic drug carrier systems. 2012; 29(1):1-63.
22. Lu XY, Hu S, Jin Y, Qiu LY. Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol. Drug development and industrial pharmacy. 2012; 38(3):314-22.
23. Kulkarni P, Vaidya K. Liposomes: A Novel Drug Delivery System. International Journal of Current Pharmaceutical Review and Research. 2010;3.
24. Kalepu S, Kt S, Betha S, M M. Liposomal drug delivery system - A Comprehensive Review. International Journal of Drug Development & Research. 2013; 5:62-75.
25. Chahar P, Cummings KC, 3rd. Liposomal bupivacaine: a review of a new bupivacaine formulation. J Pain Res. 2012; 5:257-64.
26. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. International journal of cancer. 2004; 112(4):693-700.
27. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009; 69(3):361-92.
28. Raj S, Jose S, Sumod US, Sabitha M. Nanotechnology in cosmetics: Opportunities and challenges. J Pharm Bioallied Sci. 2012; 4(3):186-93.
29. Imran M, Revol-Junelles AM, Martyn A, Tehrany EA, Jacquot M, Linder M, et al. Active food packaging evolution: transformation from micro- to nanotechnology. Critical reviews in food science and nutrition. 2010; 50(9):799-821.
30. Lauzon RJ, Brown C, Kerr L, Tiozzo S. Phagocyte dynamics in a highly regenerative urochordate: insights into development and host defense. Developmental biology. 2013; 374(2):357-73.
31. Vhora I, Patil S, Bhatt P, Misra A. Protein– and Peptide–Drug Conjugates: An Emerging Drug Delivery Technology. In: Donev R, editor. Advances in Protein Chemistry and Structural Biology. 98: Academic Press; 2015. p. 1-55.
32. Wang B, Zinselmeyer BH, Runnels HA, LaBranche TP, Morton PA, Kreisel D, et al. In vivo imaging implicates CCR2(+) monocytes as regulators of neutrophil recruitment during arthritis. Cellular immunology. 2012; 278(1-2):103-12.
33. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Ther Deliv. 2014; 5(9):1007-24.
34. Al-Jamal WT, Kostarelos K. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Accounts of chemical research. 2011; 44(10):1094-104.
35. Cortesi R, Romagnoli R, Drechsler M, Menegatti E, Zaid AN, Ravani L, et al. Liposomes- and ethosomes-associated distamycins: a comparative study. Journal of Liposome Research. 2010; 20(4):277-85.
36. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. J Microencapsul. 2018; 35(2):204-17.
Published
How to Cite
Issue
Section
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.